Molnatris 200mg Capsule is a prescription medication containing molnupiravir 200mg, indicated for the treatment of mild to moderate COVID-19 in adults who are at high risk of progressing to severe illness. Molnupiravir is a direct-acting antiviral medication that works by inhibiting the replication of SARS-CoV-2, reducing the amount of virus in the body. The product is administered orally as a capsule, once daily for 5 days. Molnatris 200mg Capsule is contraindicated in patients with severe renal impairment or end-stage renal disease, and in patients with hypersensitivity to molnupiravir. The most common adverse reactions reported in clinical trials were nausea, diarrhea, and headache. Molnatris 200mg Capsule is a prescription-only medication, and patients should be instructed to follow the recommended dosage and administration instructions carefully. As with all medications, patients should be monitored for signs and symptoms of an adverse reaction, and healthcare providers should consider the potential benefits and risks of Molnatris 200mg Capsule when prescribing it to patients.